Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Pregnancy Hypertens ; 36: 101113, 2024 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-38490151

RESUMO

OBJECTIVE: To compare rates of pregnancy induced hypertensive disorders during the period of the COVID-19 pandemic to prior, baseline years. METHODS: We conducted a retrospective study of 17,742 patients on rates for pregnancy induced hypertensive disorders delivering at 2 local hospitals before (Cohort 1; January 2018 to December 2019; n = 8245) and after (Cohort 2; February 2020 to February 2022; n = 9497) the onset of the COVID-19 pandemic. The primary outcomes were rates of gestational hypertension, pre-eclampsia, and chronic hypertension in patients.Wecompared by year (2018-2022), by patient COVID infection status, and by racial demographics. RESULTS: During the pandemic (Cohort 2), there were lower rates of chronic hypertension (7.4 % vs 6.5 %, p =.02), higher rates of gestational hypertension (26.3 % vs 27.8 %, p =.03), and higher rates of preeclampsia (11.3 % vs 13.1 %, p <.001) compared to years prior to the pandemic (Cohort 1). When evaluating by year, rates of chronic hypertension did not statistically change while rates for preeclampsia increased in the first year of the pandemic and remained high, and rates for gestational hypertension did not increase until the second year of the pandemic. When evaluating by COVID infection status, rates for gestational hypertension were significantly higher for individuals with a positive COVID infection status (COVID negative = 27.4 % vs. COVID positive = 32.8 %; p <.004). Rates of preeclampsia did not differ according to COVID infection status (p = 0.15). CONCLUSION: In this study, rates of pregnancy induced hypertensive disorders increased during the COVID pandemic regardless of COVID infection status.


Assuntos
COVID-19 , Hipertensão Induzida pela Gravidez , Humanos , Gravidez , Feminino , COVID-19/epidemiologia , Hipertensão Induzida pela Gravidez/epidemiologia , Hipertensão Induzida pela Gravidez/etnologia , Adulto , Estudos Retrospectivos , SARS-CoV-2 , Pré-Eclâmpsia/epidemiologia , Pré-Eclâmpsia/etnologia , Estados Unidos/epidemiologia
2.
Cureus ; 13(8): e17500, 2021 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-34603879

RESUMO

Cesarean scar pregnancy (CSP) is a very serious complication of a prior cesarean delivery. The major risks associated with CSP are uncontrolled hemorrhage and uterine rupture, potentially leading to future infertility. Management of CSP remains a major obstetric challenge without a well-defined therapeutic procedure. Dilation & curettage is a commonly used procedure for the treatment of CSP. However, it can be ineffective and often leads to definite infertility. Therefore, we present a case of the successful use of an alternative procedure, Myosure® hysteroscopy, in the treatment of CSP. We herein report the case of a 32-year-old G5P3013 woman who presented with vaginal bleeding and past history of three cesarean sections. She was found to have a CSP with fetal pole and cardiac activity at 6 weeks 2 days. The patient was initially treated with a systemic methotrexate injection, but there was persistence of cardiac activity. A second course of methotrexate was administered into the gestational sac, which systemically led to successful fetal cardiac arrest and downtrend of beta-human chorionic gonadotropin (HCG) level. A dilation & curettage procedure was not successful in removing products of conception. A Myosure hysteroscopy procedure, however, was successful in removing products of conception. The patient was discharged after a negative ultrasound and beta-HCG level. In our review of the literature, we found that there is no general consensus on the management of cesarean scar ectopic pregnancies. To date, there is no literature cited about the use of Myosure for cesarean scar ectopic pregnancies. However, our case suggests that Myosure can be effective for CSP and this warrants a larger-scale controlled study to better evaluate this as a treatment for this condition.

3.
Indian J Med Res ; 148(6): 743-747, 2018 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-30778009

RESUMO

BACKGROUND & OBJECTIVES: Inflammatory processes are a recognized feature of atherosclerotic lesions. Ranolazine inhibits the inflammatory markers such as C-reactive protein, interleukins-1 and -6 and tumour necrosis factor-alpha. The present study was planned to evaluate the effect of anti-inflammatory activity of ranolazine in acute and sub-acute models of inflammation in rats and compare the same with that of control (gum acacia 1%) and aspirin (standard anti-inflammatory drug). METHODS: Adult male Wistar rats (150-180 g) were used for the study. They were divided into three groups (n=6). One per cent gum acacia (control), aspirin (200 mg/kg body weight) and ranolazine (180 mg/kg body weight) were given orally. Acute inflammation was induced by injecting carrageenan in the left hind paw. Paw oedema volume and percentage inhibition were measured. Subacute inflammation was induced by implanting foreign bodies subcutaneously. Percentage inhibition of granuloma dry weight and haematoxylin and eosin stained sections of granulation tissue were studied. RESULTS: In acute and subacute model study, ranolazine significantly (P <0.01) decreased the paw oedema volume and granuloma dry weight as compared to control and it was comparable to that of aspirin and histopathological sections showed a decrease in granulation tissue formation as compared to control. INTERPRETATION & CONCLUSIONS: Ranolazine demonstrated significant anti-inflammatory activity in acute and subacute models of inflammation and needs further evaluation for its use in reducing atherosclerosis.


Assuntos
Anti-Inflamatórios não Esteroides/uso terapêutico , Edema/tratamento farmacológico , Inflamação/tratamento farmacológico , Ranolazina/uso terapêutico , Doença Aguda , Animais , Aspirina/uso terapêutico , Carragenina , Edema/etiologia , Granuloma de Corpo Estranho/tratamento farmacológico , Granuloma de Corpo Estranho/patologia , Goma Arábica/uso terapêutico , Inflamação/induzido quimicamente , Inflamação/complicações , Masculino , Distribuição Aleatória , Ratos Wistar
4.
J Pharm Bioallied Sci ; 7(Suppl 1): S291-5, 2015 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-26015736

RESUMO

Calcifying epithelial odontogenic tumor (CEOT) also known as Pindborg tumor is a rare odontogenic epithelial neoplasm. So far nearly 200 cases have been reported in literature. We are reporting a case of CEOT in a 42-year-old male patient with painless bony swelling in the mandible. Approximately, 50% of the cases are associated with an unerupted tooth or odontome, but was not so with our case. Considering the intrabony mandibular location of the lesion and its limited size, we opted for a more conservative surgery. The clinical, radiographic and histopathologic features and the surgical treatment done are discussed with relevant references.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...